Primary publications: GAC.1 and IND.213

Planned System Maintenance

Starting Friday, December 21st, 2018 beginning at 5:00 PM EST, and ending on Friday, December 21st, 2018 at 11:00 PM EST. During this time there will be no access to the system including patient enrollments.
Please share this notification to the personnel who will be affected by this within your organization.
Maintenance Start: Friday, December 21st, 2018, 5:00 PM EST.
Maintenance End: Friday, December 21st, 2018, 11:00 PM EST.
We are sorry for any inconvenience this may cause.

Wednesday, November 1, 2017

Primary publication: GAC.1

Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance) (ONLINE). J Clin Oncol JCO, 2017. http://ascopubs.org/doi/full/10.1200/JCO.2017.74.2130

To determine whether overall survival is prolonged in patients with resected gastric adenocarcinoma who receive epirubicin, cisplatin and infusional 5-FU (ECF) before and after infusional 5-FU plus radiotherapy (RT) when compared to those treated with bolus 5-FU and leucovorin before and after infusional 5-FU plus RT. Phase III Randomized Study of Adjuvant Chemoradiation After Resection in Patients with Gastric or Gastroesophageal Adenocarcinoma.

 

Primary publication: IND.213

Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213 (ONLINE). Breast Cancer Res Treat 2017. https://link.springer.com/article/10.1007%2Fs10549-017-4538-4

For patients with Metastatic Breast Cancer. A PhaseII trial aimed at the evaluation the side effects of Reolysin when given together with paclitaxel. As these drugs have not been given together before, 6-9 patients will be treated with paclitaxel plus reolysin to ensure that side effects are tolerable.